-
br In the following studies we have investigated the abiliti
2020-03-24
In the following studies, we have investigated the abilities of NAX compounds to interact with metformin and inhibit the growth of PDAC cell lines. We have investigated the effects of the introduction of one phenyl moiety (NAX012, NAX042), two phenyl moieties (benzhydryl) (NAX035, NAX053) and one h
-
br We next performed microarray analysis of
2020-03-24
We next performed microarray analysis of mouse endometrium under estrogen and high-fat diet intervention and found a gene set as-sociated with ubiquitin enzymes was dysregulated (Fig. 2C). CD163+ macrophage CM intervention further confirmed the same change in ubiquitin enzymes in HEC-1A Haloperido
-
br Author contributions br All authors contributed to the
2020-03-24
Author contributions All authors contributed to the conception and design of the study or to the data acquisition. LR performed the statistical analysis and drafted the manuscript. All authors interpreted the data. HJ, LFV, LBJT, BVO and PV provided critical revision of the manuscript for impor
-
b iframe width height src https www
2020-03-17
r> The remainder of this Seladelpar paper is organized as follows. Section 2 introduces the related work on the application of machine learning methods to cancer survivability prediction and ensemble learning methods. Section 3 presents details of the pro-posed two-stage model. Section 4 describes
-
br Methods A systematic review
2020-03-17
Methods: A systematic review of relevant studies was performed through online databases using predefined criteria. The most updated studies were selected for meta-analysis according to unmatched and matched patient cohorts. Results: Thirty-two studies were identified in the systematic review, a
-
Bener A Honein G Carter A Da ar
2019-11-12
12. Bener A, Honein G, Carter A, Da’ar Z, Miller C, Dunn E. The determinants of breast cancer screening behavior: a focus group study of women in the United Arab Emirates. Oncol Nurs Forum 2002;29(9):91e8. 13. Thomas V, Saleem T, Abraham R. Barriers to effective uptake of cancer screening among bla
-
br D J O Shannessy
2019-11-05
[7] D.J. O'Shannessy, E.B. Somers, L.M. Palmer, R.P. Thiel, P. Oberoi, R. Heath, et al., Serum folate GSK1838705A alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4, J Ovarian Res 6 (1) (2013) 29. [1
-
br tively but does not inhibit any
2019-10-29
tively) but does not inhibit any of the other ALDH family members tested (Figure 2B). Similar to 673A, CM10 inhibits ALDEFLUOR activity in live Trizma maleate (Figure S2D), and preferentially depletes CD133+ cells (Figures 2A and S2E). PubChem searches sug-gested CM10 and 673A (active in 17 of 673
-
br Corresponding author Corresponding author
2019-10-29
∗ Corresponding author. ∗∗ Corresponding author. ∗∗∗ Corresponding author. E-mail addresses: [email protected] (J. Liu), [email protected] (X. Zhang), [email protected] (G. Yang). 1 Authors contributed equally. reach hundreds of units per liter (Gowda et al., 2009). Therefore, a po
-
br Discussion br Mitochondria are not
2019-10-21
4. Discussion Mitochondria are not only the powerhouse of cells, but also their suicidal arsenal. Lots of suicidal signal transduction pathways con-centrate on mitochondria to induce the mitochondrial permeability transition, resulting in the release of pro-apoptotic proteins to cyto-plasm (Ful
-
br Manning Geist et al A
2019-10-21
Manning-Geist et al. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol 2019. compared with patients with SO-residual disease (23.2 vs 14.7 months; 33 vs 22 months; 38 vs 15 m
-
br Pai HH Pickles T Keyes M et al Randomized
2019-10-15
32. Pai HH, Pickles T, Keyes M, et al. Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists. Can Urol Assoc J 2011;5:173-179. European Journal of Pharmaceutics and Biopharmaceutics 142 (2019) 49–60 Contents lists avail
-
br Table Patient characteristics stratified by training and
2019-10-15
Table 2 Patient characteristics stratified by training and validation cohorts Training Validation cohort cohort Characteristic Age at diagnosis, y Median Stage grouping Baseline PSA Median Baseline testosterone Charlson Comorbidity Index Median IQR
-
br We noted that atalantraflavone treatment may
2019-10-14
We noted that atalantraflavone treatment may facilitate cellular apoptosis in cisplatin resistant NSCLC Epoprostenol with massively observable cleaved forms of PARP and caspase-3. The sub-G1 fraction and apoptotic rates were evidently increased with atalantraflavone treatment. In current research
-
br Table e Intraoperative outcome br CLR NOSES P value
2019-10-14
Table 2 e Intraoperative outcome. CLR NOSES P value mean (range) nodes, mean (range) complications, n (%) mean (range) CLR ¼ conventional laparoscopic resection; NOSES ¼ natural orifice specimen extraction surgery. compared with those in the NOSES group, the difference did n